Search the Newsreel

Mizuho lowers Corbus Pharmaceuticals stock price target on model updates By Investing.com

Mizuho has lowered its price target for Corbus Pharmaceuticals (NASDAQ: CRBP) to $33 from $34, while maintaining an Outperform rating. The adjustment follows minor model updates after the company's second-quarter results, with no material changes noted by Mizuho. Corbus has two key pipeline candidates, …

Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock

Corbus Pharmaceuticals insider Nishant Saxena recently bought 2,600 shares, increasing his stake by 3.45%, despite the company reporting weaker-than-expected quarterly earnings and facing some analyst downgrades. The stock has seen a 342% year-to-date surge, and institutional investors hold a significant portion of the company. …

Research Analysts Set Expectations for CRBP Q3 Earnings

Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals CFO Sean Moran sold 12,000 shares of the company's stock for over $120,000, reducing his direct stake by 12.41%. This sale occurred as CRBP shares fell 7.0% to $9.46, and the company reported a quarterly loss worse than analyst expectations. Despite this, …

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts

Corbus Pharmaceuticals (NASDAQ:CRBP) has received a "Moderate Buy" consensus rating from ten brokerages, with eight "buy" and two "sell" recommendations. The average 12-month price target is $41.13, despite some recent downward adjustments. The company missed its quarterly EPS expectations, reporting -$1.81 against an estimated …

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. (CRBP) stock dropped 6.98% on Monday, closing at $9.46. This underperformance occurred during a generally poor trading session for the market, with both the NASDAQ Composite Index and Dow Jones Industrial Average also declining. The fall broke a four-day winning …

Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Yuval Cohen Sells 17,000 Shares of Stock

Corbus Pharmaceuticals CEO Yuval Cohen sold 17,000 shares of the company's stock, valued at $171,360, reducing his position by 9.75%. The transaction occurred on August 7th, with shares sold at an average price of $10.08. Despite an earnings miss, the company holds a "Moderate …

Corbus Pharmaceuticals Holdings Inc Actuals & Estimates (NASDAQ:CRBP)

This article provides an overview of Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock, including its current price, historical performance, analyst forecasts, and financial data. It details key metrics such as market capitalization, earnings, revenue, and employee count, and offers insights into its volatility and technical …

Corbus Pharmaceuticals (NASDAQ:CRBP) Cut to "Strong Sell" at Wall Street Zen

Wall Street Zen has downgraded Corbus Pharmaceuticals (NASDAQ:CRBP) to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy." This comes after the company reported a quarterly EPS of -$1.81, missing analyst estimates, and saw mixed insider activity with both purchases and …

Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Corbus Pharmaceuticals Holdings Inc (CRBP) has an earnings forecast score of 9.00 and an average price target of $39.00 from analysts. The stock is rated as a "Strong Buy" by 10 analysts, with a potential upside of 297.16%. The expected revenue for the next …

Corbus Pharmaceuticals Holdings Inc (CRBP) Stock News Today

CRBP (NASDAQ: CRBP) insider plans 12,000-share sale via Stifel

An affiliate of Corbus Pharmaceuticals Holdings, Inc. (CRBP) has filed a Form 144, indicating an intent to sell up to 12,000 shares of common stock through Stifel Nicolaus & Company Inc. on or after August 7, 2026. The shares, valued at an aggregate market …

CRBP (CRBP) holder files to sell 17,000 Nasdaq-traded shares

A Corbus Pharmaceuticals Holdings, Inc. (CRBP) shareholder has filed a Form 144, indicating an intention to sell 17,000 shares of common stock through Stifel Nicolaus & Company Inc. The proposed sale, valued at $171,396.00, is slated for August 7, 2026, on Nasdaq. The shares …

Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating

Oppenheimer has revised its price target for Corbus Pharmaceuticals Holdings, Inc. to $48 from $52, while reiterating an "Outperform" rating on the stock. This adjustment comes amidst other recent news for Corbus Pharmaceuticals, including earnings results and progress in its clinical trials for obesity …

HC Wainwright Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price

Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary

Corbus Pharmaceuticals Holdings, Inc. has released its earnings summary for the quarter that ended on June 30. The full article can be accessed through TradingView, which offers unlimited access to news from Reuters and other sources.

Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial

Corbus Pharmaceuticals reported a significant increase in its Q2 2026 net loss, reaching $35.0 million compared to $17.7 million in Q2 2025, primarily due to increased clinical development spending including a $10.0 million milestone payment. Despite the wider loss, the company secured FDA clearance …

Form 8K Corbus Pharmaceuticals Holding For: 6 August By Investing.com

This article from Investing.com reports that Corbus Pharmaceuticals Holding filed a Form 8K on August 6th. The Form 8K filing is a routine disclosure document that companies must file with the SEC for significant events. The article provides minimal detail beyond the fact of …

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals announced its Q2 2026 financial results and provided a corporate update, highlighting progress in its oncology and obesity programs. The company received FDA clearance for its TEMPO-1 registrational study of CRB-701 in oropharyngeal cancer and expects to initiate enrollment in September 2026. …

Corbus Pharmaceuticals (CRBP) Earnings Date and Reports 2026

Corbus Pharmaceuticals (CRBP) Holds Gains as Biotech Momentum Builds - Volatility Breakout Picks

Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (CRBP) Completes Final Patient Visit in CANYON-1 Trial, Eyes September Topline Results

Corbus Pharmaceuticals (CRBP) has completed the final patient visit in its CANYON-1 Phase 1b trial for CRB-913, an oral obesity treatment, with topline results expected in September. The company trades at a significantly high Price-to-Sales ratio, reflecting market anticipation of future growth despite current …

Obesity Treatment Study Reaches Final Visit; Corbus Data Expected in September

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that the last patient has completed the final visit in its CANYON-1 Phase 1b trial for CRB-913, an obesity treatment, with topline data anticipated in September 2026. The study is a 16-week, double-blind, placebo-controlled trial involving 240 obese, non-diabetic …

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals announced the completion of the last patient's last visit in its CANYON-1 Phase 1b clinical trial for CRB-913, an oral CB1 inverse agonist for obesity treatment. Topline data from this dose-finding study are expected in September 2026. CRB-913 aims to offer a …

(CRBP) Price Dynamics and Execution-Aware Positioning

This article provides an in-depth analysis of Corbus Pharmaceuticals Holdings Inc. (CRBP) stock dynamics, highlighting a near-term weak sentiment that may lead to long-term weakness. It identifies a significant risk-reward setup targeting a 35.4% gain against a 0.2% risk and outlines three institutional trading …

Corbus Pharmaceuticals Holdings Inc Revenue Breakdown – HAM:3371

This page on TradingView provides financial information for Corbus Pharmaceuticals Holdings Inc (HAM:3371). It offers an overview of fundamentals, statements, statistics, dividends, earnings, and segments. The market for this stock was closed at the time of viewing with no trades reported.

CRBP|Corbus Pharmaceuticals Holdings Inc|Price:8.931|Chg%:-0.039

Corbus Pharmaceuticals Holdings Inc (CRBP) has a TradingKey Stock Score indicating weak fundamentals but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is very high, and analysts have rated it as a Strong Buy …

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day

Corbus Pharmaceuticals Holdings Inc. (CRBP) stock decreased by 1.82% to $8.92 on Wednesday, underperforming the broader market which saw the NASDAQ Composite Index fall by 1.74% and the Dow Jones Industrial Average fall by 2.19%. Despite the daily loss, the article's title suggests the …

Form 144 Corbus Pharmaceuticals Holdings For: 27 July By Investing.com

Investing.com reported on a Form 144 filing for Corbus Pharmaceuticals Holdings, indicating activity for July 27th. The article is a brief financial news item, referencing the regulatory filing for the company.

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals Holdings, Inc. announced that the FDA has cleared the initiation of its TEMPO-1 registrational study for CRB-701, an antibody drug conjugate targeting Nectin-4, for second-line oropharyngeal squamous cell carcinoma (OPSCC). The company expects to begin enrollment in September 2026, aiming for potential …

BlackRock, Inc. (CRBP) discloses 5.9% beneficial ownership in Corbus Pharmaceuticals

BlackRock, Inc. has disclosed a 5.9% beneficial ownership stake in Corbus Pharmaceuticals Holdings Inc. through a SCHEDULE 13G SEC filing. This report indicates that BlackRock beneficially owns 1,093,434 shares of Corbus common stock, with sole voting power over 1,081,182 shares and sole dispositive power …

Corbus Pharmaceuticals Holdings Inc (CRBP) Cash Flow

This article provides a detailed cash flow statement for Corbus Pharmaceuticals Holdings Inc (CRBP), breaking down operating, investing, and financing cash flows quarterly and annually. It includes historical data and year-over-year percentage changes for various cash flow components. The report also features an FAQ …